Locations:
Search IconSearch
June 18, 2019/Neurosciences

Identifying Risks Factors Associated With Extended Length of Stay in Posterior Segmental Instrumented Fusion for Adolescent Idiopathic Scoliosis

Effective pain relief and major postoperative complications correlate with length of stay, study finds

16-ort-2676-goodwin-hero-image-650x450pxl

The use of epidural analgesia (EA) may be a protective factor against extended length of stay (LLOS) in patients undergoing posterior segmental instrumented fusion (PSIF) for adolescent idiopathic scoliosis (AIS).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A retrospective cohort study, recently published in the journal Spine Deformity, analyzed a variety of demographic and surgical factors in order to identify independent risk factors associated with increased LOS. The two factors most strongly associated with LLOS were major postoperative complications and the use of EAs for pain management. Other factors with statistically significant correlations were female sex, ≥9 ±2 levels of fusion, amount of operative blood loss, major postoperative complications, lack of EA and higher thoracic kyphosis.

“Length of stay is important in an era of value-based care; however, studies such as this one are concerned with more than reimbursement,” states Ryan Goodwin, MD, Director of Cleveland Clinic’s Center for Pediatric and Adolescent Orthopaedics. “The modifiable risk factors we identified, such as effective pain relief and major postoperative complications, relate to patient safety and well-being and overall quality of care.”

Identifying risks factors associated with extended length of stay

The study involved retrospective analysis of data from pediatric scoliosis patients (n = 407) undergoing surgical correction from January 1, 2009 through December 31, 2017. Researchers defined a short length of stay (SLOS) as fewer than four days, and a LLOS as four or more days.

Of the patients included in this single-institution study, 232 had SLOS, with a mean stay of 3 ±0.5 days. The remaining 175 patients had LLOS, with a mean stay of 6 ±2 days. Researchers looked at factors related to a patient’s demographics, comorbidities and preoperative measurements of scoliosis curve, as well as factors related to the surgery itself and any complications.

Advertisement

Among the demographic characteristics, only female sex had statistically significant associations with LLOS. Higher thoracic kyphosis was the only preoperative radiographic measurement to correlate with LLOS. Comorbidities had no statistically significant impact on LOS.

In terms of surgery-related characteristics and postoperative complications, which might be considered somewhat modifiable risk factors, operative time and the number of osteotomies had no significant impact on LOS. Patients in whom 7 ±2 levels were fused had SLOS compared to patients who had 9 ±2 levels fused.

Opportunity to make meaningful improvements in quality of care

In patients with major postoperative complications, such as the development of motor weakness, the need for transfusion, infection or reoperation, the risk of LLOS increased 11-fold. Patients without EA for pain control, a modifiable factor, had a three-fold increased risk of LLOS. Comorbidities, preoperative curve Cobb angle and number of osteotomies did not have a statistically significant impact on LOS.

Dr. Goodwin notes, “To our knowledge, this is the largest single-institution study, looking at the most comprehensive list of potential risk factors that might impact length of stay in this patient population. One day in a U.S. hospital can cost up to $4,000. Lowering these costs by reducing the number of in-hospital recovery days is good for everyone involved—patients, providers and payers.”

Advertisement

Related Articles

middle-aged woman with surgical mask looking out a window
Registry Studies Reassure on Impact of COVID-19 in People With MS

No effect on symptom severity or disability, and low prevalence of long COVID

network of nerves on the side of the face
January 14, 2025/Neurosciences/Brain Tumor
Preemptive Facial Nerve Rewiring in the Management of Facial Nerve Tumor: A Case Study

Novel approach begins reinnervation before tumor resection, preserving a young woman’s smile

Medical illustration of brain
January 6, 2025/Neurosciences/Research
Department of Defense Awards $3.4 Million to Advance a Tool for Assessing Return-to-Duty Readiness After Brain Injury

Cleveland Clinic researchers collaborate with Microsoft to create a product ready for the field

smartwatch being strapped to a woman's wrist
December 20, 2024/Neurosciences/Brain Tumor
Can Smartwatch Data Predict Progression and Detect Complications in Patients With Glioblastoma?

Researchers use AI tools to compare clinical events with continuous patient monitoring

Dr. Charles Bernick against a decorative backdrop
December 13, 2024/Neurosciences/Podcast
Considerations Around the Use of Anti-Amyloid Agents for Alzheimer’s Disease (Podcast)

Guidance on patient selection, safety surveillance, choosing among agents and more

macrophages and microglia in glioblastoma tumors
December 3, 2024/Neurosciences/Brain Tumor
Dual Targeting of Macrophages and Microglia Shows Promise in Preclinical Glioblastoma Models

Combining dual inhibition with anti-PD1 therapy yielded >60% rate of complete tumor regression

portrait of dr. demitre serletis against decorative background
December 2, 2024/Neurosciences/Podcast
SEEG in Epilepsy Surgery Evaluation: Current and Future Roles (Podcast)

Insights on how stereoelectroencephalography is continuing to improve seizure localization

brain map showing planned electrode placement
November 25, 2024/Neurosciences/Epilepsy
What We’ve Learned From Our First 1,000 Cases of SEEG Evaluation

Progress in stereoelectroencephalography for epilepsy surgery evaluation since Cleveland Clinic performed the first U.S. case in 2009

Ad